Advanced Search

Show simple item record

dc.contributor.authorÖztürk, Alper
dc.contributor.authorAlço, Gül
dc.contributor.authorSarsenov, Dauren
dc.contributor.authorİlgün, Serkan
dc.contributor.authorOrdu, Çetin
dc.contributor.authorKöksal, Ülkühan
dc.contributor.authorPilancı, Kezban Nur
dc.contributor.authorErdoğan, Zeynep
dc.contributor.authorİzci, Filiz
dc.contributor.authorElbuken, Filiz
dc.contributor.authorAgacayak, Filiz
dc.contributor.authorAktepe, Fatma
dc.contributor.authorÖzmen, Vahit
dc.date.accessioned30.04.201910:49:13
dc.date.accessioned2019-05-30T20:33:21Z
dc.date.available30.04.201910:49:13
dc.date.available2019-05-30T20:33:21Z
dc.date.issued2018
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.urihttps://hdl.handle.net/20.500.12445/649
dc.description.abstractPurpose: The objective of this study was to assess the demographic, pathologic and survival characteristics of patients who were diagnosed as having bilateral breast cancer. Methods: A review was conducted of the records pertaining to patients who presented to our clinic and were diagnosed as having breast cancer. Any second cancer diagnosed within 12 months of initial diagnosis was defined as synchronous bilateral breast cancer. Assessment included treatments administered to the patients and survival rates, as well as their demographic, reproductive and pathologic features. Results: The total number of patients who were diagnosed as having bilateral breast cancer in the context of the present study was 99. Among the patients with synchronous breast cancer, the median age at the time of initial diagnosis was found as 57 years. The median age of the discovery of first tumor among the patients with metachronous tumor was 52 years and the median age of second tumor detection was 59 years. Family history in metachronous tumor was significantly greater (p =0.041). The median time of metachronous cancer incidence was 96 months. The length of disease-free period among the patients with synchronous tumor was 126.3 months, whereas it was 243.7 months in those with metachronous tumor (p=0.041). Conclusion: The incidence rate of synchronous breast tumors has been rising thanks to growing awareness and the leading-edge imaging methods. The fact that the second tumor developed after more than 5 years among the patients with metachronous cancer gave rise to the increased rate of survival.en_US
dc.language.isoengen_US
dc.publisherImprimatur Publicationsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectBilateralen_US
dc.subjectMetachronousen_US
dc.subjectSynchronousen_US
dc.titleSynchronous and metachronous bilateral breast cancer: A long-term experienceen_US
dc.typearticleen_US
dc.relation.journalJournal of Buonen_US
dc.contributor.departmentBiruni Üniversitesien_US
dc.contributor.authorID0000-0002-4862-2891en_US
dc.identifier.volume23en_US
dc.identifier.issue6en_US
dc.identifier.startpage1591en_US
dc.identifier.endpage1600en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record